These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33086575)

  • 21. Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
    Lima L; Neves M; Oliveira MI; Dieguez L; Freitas R; Azevedo R; Gaiteiro C; Soares J; Ferreira D; Peixoto A; Fernandes E; Montezuma D; Tavares A; Ribeiro R; Castro A; Oliveira M; Fraga A; Reis CA; Santos LL; Ferreira JA
    Urol Oncol; 2017 Dec; 35(12):675.e1-675.e8. PubMed ID: 28911924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
    Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.
    Piao XM; Kang HW; Jeong P; Byun YJ; Lee HY; Kim K; Seo SP; Kim WT; Lee JY; Ha YS; Choi YH; Moon SK; Yun SJ; Kim WJ
    Urol Oncol; 2021 Apr; 39(4):237.e21-237.e29. PubMed ID: 33339725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
    Biton A; Bernard-Pierrot I; Lou Y; Krucker C; Chapeaublanc E; Rubio-Pérez C; López-Bigas N; Kamoun A; Neuzillet Y; Gestraud P; Grieco L; Rebouissou S; de Reyniès A; Benhamou S; Lebret T; Southgate J; Barillot E; Allory Y; Zinovyev A; Radvanyi F
    Cell Rep; 2014 Nov; 9(4):1235-45. PubMed ID: 25456126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.
    Yang D; Ma Y; Zhao P; Ma J; He C
    Biomed Pharmacother; 2019 Dec; 120():109433. PubMed ID: 31568988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
    Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
    J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer.
    Bielli P; Panzeri V; Lattanzio R; Mutascio S; Pieraccioli M; Volpe E; Pagliarulo V; Piantelli M; Giannantoni A; Di Stasi SM; Sette C
    Clin Cancer Res; 2018 Nov; 24(21):5422-5432. PubMed ID: 30012566
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteome-based classification of Nonmuscle Invasive Bladder Cancer.
    Stroggilos R; Mokou M; Latosinska A; Makridakis M; Lygirou V; Mavrogeorgis E; Drekolias D; Frantzi M; Mullen W; Fragkoulis C; Stasinopoulos K; Papadopoulos G; Stathouros G; Lazaris AC; Makrythanasis P; Ntoumas K; Mischak H; Zoidakis J; Vlahou A
    Int J Cancer; 2020 Jan; 146(1):281-294. PubMed ID: 31286493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling in bladder cancer identifies potential therapeutic targets.
    Hussain SA; Palmer DH; Syn WK; Sacco JJ; Greensmith RMD; Elmetwali T; Aachi V; Lloyd BH; Jithesh PV; Arrand J; Barton D; Ansari J; Sibson DR; James ND
    Int J Oncol; 2017 Apr; 50(4):1147-1159. PubMed ID: 28259975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
    van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
    Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
    Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
    Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
    Kim D; Choi Y; Ireland J; Foreman O; Tam RN; Patel R; Schleifman EB; Motlhabi M; French D; Wong CV; Peters E; Molinero L; Raja R; Amler LC; Hampton GM; Lackner MR; Kabbarah O
    PLoS One; 2016; 11(11):e0165856. PubMed ID: 27846280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.
    Piao XM; Kim SK; Byun YJ; Zheng CM; Kang HW; Kim WT; Kim YJ; Lee SC; Kim WJ; Moon SK; Choi YH; Yun SJ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
    Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
    J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
    Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
    Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.